220
Participants
Start Date
November 25, 2019
Primary Completion Date
March 8, 2021
Study Completion Date
January 7, 2022
BMS-986165
Specified dose on Specified Days
Placebo
Specified dose on Specified days
Local Institution - 0031, Taipei
Local Institution - 0033, Goyang-si
Local Institution - 0032, Taipei
Local Institution - 0022, Seongnam-si
Local Institution - 0037, Seongnam-si
Local Institution - 0034, Bucheon-si
Local Institution - 0023, Suwon
Local Institution - 0035, Incheon
Local Institution - 0025, Taoyuan District
Local Institution - 0028, Gwangju
Local Institution - 0029, Kaohsiung City
Local Institution - 0001, Beijing
Local Institution - 0007, Beijing
Local Institution - 0014, Beijing
Local Institution - 0006, Dalian
Local Institution - 0002, Changchun
Local Institution - 0012, Jingan
Local Institution, Nanjing
Local Institution - 0009, Hangzhou
Local Institution - 0003, Hangzhou
Local Institution - 0004, Hangzhou
Local Institution, Changsha
Local Institution - 0011, Wuhan
Local Institution - 0016, Wuhan
Local Institution, Chengdu
Local Institution - 0008, Chongqing
Local Institution - 0018, Taiyuan
Local Institution - 0036, Seoul
Local Institution - 0026, Seoul
Local Institution, Seoul
Local Institution - 0021, Seoul
Local Institution - 0020, Seoul
Local Institution - 0027, Seoul
Local Institution - 0024, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY